Highmark Commercial Medical Policy - Pennsylvania |
Medical Policy: | M-77-002 |
Topic: | Upper Gastrointestinal Endoscopy/Esophagoscopy |
Section: | Diagnostic Medical |
Effective Date: | September 25, 2017 |
Issue Date: | September 25, 2017 |
Last Reviewed: | August 2017 |
Esophagogastroduodenoscopy (EGD)/upper endoscopy is performed to view mucosal surfaces of the esophagus, stomach, and proximal duodenum for screening, diagnostic and therapeutic purposes. |
This policy is designed to address medical guidelines that are appropriate for the majority of individuals with a particular disease, illness, or condition. Each person's unique clinical circumstances may warrant individual consideration, based on review of applicable medical records.
Policy Position Coverage is subject to the specific terms of the member’s benefit plan. |
High Risk Screening EGD
EGD/upper endoscopy may be considered medically necessary for high risk screening for ANY of the following conditions:
All other indications for high risk screening EGD are considered experimental/investigational and, therefore, non-covered. The safety and/or effectiveness cannot be established by review of the available published peer-reviewed literature. |
Diagnostic EGD
Diagnostic EGD may be considered medically necessary for ANY of the following conditions:
All other indications for diagnostic EGD are considered experimental/investigational and, therefore, non-covered. The safety and/or effectiveness cannot be established by review of the available published peer-reviewed literature.
Therapeutic EGD
Therapeutic EGD may be considered medically necessary for ANY of the following conditions:
All other indications for therapeutic EGD are considered experimental/investigational and, therefore, non-covered. The safety and/or effectiveness cannot be established by review of the available published peer-reviewed literature.
Sequential or Periodic EGD
Sequential or periodic EGD may be considered medically necessary for ANY of the following conditions:
All other indications for sequential or periodic EGD are considered experimental/investigational and, therefore, non-covered. The safety and/or effectiveness cannot be established by review of the available published peer-reviewed literature.
Refer to medical policy HMK S-4 Endoscopic Procedures and Related Services for additional information. Refer to medical policy HMK S-145 Transesophageal Endoscopic Therapies for Gastroesophageal Reflux Disease (GERD) for additional information. Refer to medical policy HMKS-204 Radiofrequency Ablation of the Esophagus, Nonvariceal Gastrointestinal Bleeding and Anemia for additional information. Refer to medical policy S-233 Magnetic Esophageal Ring to Treat Gastroesophageal Reflux Disease for additional information. |
Place of Service: Inpatient/Outpatient |
Experimental/Investigational (E/I) services are not covered regardless of place of service.
Upper gastrointestinal endoscopy is typically an outpatient procedure which is only eligible for coverage as an inpatient procedure in special circumstances, including, but not limited to, the presence of a co-morbid condition that would require monitoring in a more controlled environment such as the inpatient setting.
The policy position applies to all commercial lines of business |
Denial Statements |
Services that do not meet the criteria of this policy will be considered experimental/investigational (E/I). A network provider can bill the member for the experimental/investigational service. The provider must give advance written notice informing the member that the service has been deemed E/I. The member must be provided with an estimate of the cost and the member must agree in writing to assume financial responsibility in advance of receiving the service. The signed agreement must be maintained in the provider’s records.
Links |
02/2017 New Coverage Position for Upper Gastrointestinal Endoscopy